Investor Relations

Print   Email  
Stock price graph
     

Ocera is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with acute and chronic liver disease, an area of high unmet medical need. Ocera's lead program, OCR-002, is an ammonia scavenger designed to treat hyperammonemia (elevated ammonia in the blood) and associated hepatic encephalopathy, a complication of patients with liver cirrhosis.

View all »   RSSRecent Releases

May 4, 2015
Ocera CEO to be Honored at the 17th Annual American Liver Foundation's Salute to Excellence Awards Gala in San Francisco

May 4, 2015
Ocera Therapeutics Announces Change in Executive Team

View all »Events & Presentations

Jun 24, 2015 at 10:00 AM ET
JMP Securities Life Sciences Conference

Investors